title: [New options for the practice : Update S1/S2 guidelines on rheumatoid arthritis?]
abstract: Guidelines are important tools for evidence-based pharmacological treatment of patients suffering from rheumatoid arthritis. Recommendations assist physicians in identifying the best form of treatment but ultimately, the final decision is based on joint participation by the patient and physician. Nowadays, general concepts, such as treat to target seem to be more important in rheumatoid arthritis than differencies between various drugs or drug classes. The universal recommendation to use methotrexate as the initial disease-modifying antirheumatic drug (DMARD) is driven more by economic reasons than by scientific data, which is not completely wrong but should be disclosed. For the future, more differentiated recommendations need better individual risk stratification and more distinct profiling of the different substances.
authors.affiliation: Poliklinik und Funktionsbereich für Rheumatologie, Hiller Forschungszentrum, Heinrich-Heine-Universität Universitätsklinikum Düsseldorf, HHUD Moorenstr. 5, 40225, Düsseldorf, Deutschland. Matthias.Schneider@med.uni-duesseldorf.de.
authors.forename: M
authors.initials: M
authors.lastname: Schneider
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000628:therapy*; D000066491:Clinical Decision-Making / Q000379:methods; D019317:Evidence-Based Medicine / Q000592:standards / Q000639:trends; D005544:Forecasting; D005858:Germany; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D017063:Outcome Assessment, Health Care / Q000592:standards / Q000639:trends; D017410:Practice Guidelines as Topic; D012219:Rheumatology / Q000592:standards* / Q000639:trends; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate
keywords: Disease modifying antirheumatic drugs; Evidence; Methotrexate; Pharmaceuticals; Risk stratification